[1] Williams DO, Holubkov R, Yeh W, et al.Percutaneous coronary intervention in the current era compared with 1985-1986:The national Heart, Lung, and Blood Institute Registries[J]. Circulation, 2000, 102(24): 2910-2914. [2] Dale WE, Batra PS, Blaaine EH, et al.Enhanced neointimal growth in cultured rabbit aorta following in vivo balloon angioplasty[J]. In vivo Cell Dev Biol Anim, 1998, 34(10): 805-812. [3] Gibbons GH, Dzau VJ.Molecular therapies for vascular disease[J]. Science, 1996, 272(7): 689-692. [4] Pickart CM.Back to the future with ubiquitin[J]. Cell, 2004, 116(2): 181-190. [5] Herrmann J, Edwards WD, Holmes DR Jr, et al. Increased ubiquitin immunoreactivity in unstable atherosclerotic plaques associated with acute coronary syndromes [J]. J Am Coll Cardiol, 2002, 40(11): 1919-1927. [6] Hermann J, Gulati R, Napoli C, et al.Oxidative stressrelated increase in ubiquitination in early coronary atherogenesis[J]. FASEB J, 2003, 17(12): 1730-1732. [7] Li QZ, Yang YZ, Yi GH, et al. Establishment of a novel foam cell model from human monocytic U937 cell line[J]. Chin J Arterioscler, 1999, 7(2): 152-154. [8] Yang XD, Yang YZ, Li J, et al.Mechanism involved in the apoptosis of U937 cells induced by oxidized low density lipoprotein[J]. Pro Biochem Biophy, 2000, 27(2): 197- 200. [9] Isner JM. Vascular remodeling: Honey, I think.I shrunk the artery[J]. Circulation, 1994, 89(6): 2937-2941. [10] Drexler HCA.Activation of the cell death program by inhibition of proteasome function[J]. Proc Natl Acad Sci, 1997, 94(3): 855-860. [11] Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors:a novel class of potent and effective antitumor agents[J]. Cancer Res, 1999, 59(11): 2615-2622 |